Aaron Cowen Suvretta Capital Management
Aaron Cowen is the founder of Suvretta Capital Management, a long/short equity firm with a fundamental research process. The firm invests across sectors with an emphasis on differentiated fundamental views. Cowen’s disclosures are tracked by investors who follow mid-to-large fundamental hedge funds.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$71.7M |
| 2 |
Biohaven
BHVN
|
+$47.3M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$42.1M |
| 4 |
Sysco
SYY
|
+$38.9M |
| 5 |
Apple
AAPL
|
+$34.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
argenx
ARGX
|
+$48M |
| 2 |
Cigna
CI
|
+$45.6M |
| 3 |
McKesson
MCK
|
+$30.5M |
| 4 |
Verizon
VZ
|
+$23M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
+$22.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.12% |
| 2 | Technology | 10.09% |
| 3 | Communication Services | 6.22% |
| 4 | Consumer Discretionary | 5.49% |
| 5 | Financials | 2.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Monte Rosa Therapeutics
GLUE
$1.22B
| $9.94M | 0.37% |
+2,659,000
| New | +$13.6M |
|
52
Alnylam Pharmaceuticals
ALNY
$31.6B
| $9.14M | 0.34% |
37,624
+4,964
| +15% | +$784K |
|
53
GE HealthCare
GEHC
$33.8B
| $5.84M | 0.21% |
75,000
| – | – |
|
|
MRNS
54
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $4.47M | 0.16% |
3,820,012
-1,288,508
| -25% | -$3.22M |
|
55
Teva Pharmaceuticals
TEVA
$43.5B
| $4.36M | 0.16% |
268,100
| – | – |
|
|
KZR
56
DELISTED
Kezar Life Sciences
KZR
| $4.3M | 0.16% |
716,759
| – | – |
|
57
Danaher
DHR
$154B
| $4.1M | 0.15% |
16,427
| – | – |
|
58
Thermo Fisher Scientific
TMO
$233B
| $4.01M | 0.15% |
7,260
| – | – |
|
|
EXAS
59
DELISTED
Exact Sciences
EXAS
| $3.98M | 0.15% |
+94,100
| New | +$5.18M |
|
60
Elanco Animal Health
ELAN
$12B
| $3.66M | 0.13% |
253,600
-253,600
| -50% | -$4.05M |
|
61
Abbott
ABT
$202B
| $3.48M | 0.13% |
33,520
| – | – |
|
62
Gilead Sciences
GILD
$181B
| $3.48M | 0.13% |
50,700
| – | – |
|
63
Kenvue
KVUE
$36.6B
| $3.12M | 0.11% |
171,596
| – | – |
|
|
MOLN
64
Molecular Partners
MOLN
$165M
| $2.89M | 0.11% |
400,000
| – | – |
|
65
Cencora
COR
$60.7B
| $2.81M | 0.1% |
12,488
| – | – |
|
66
Mettler-Toledo International
MTD
$28B
| $2.74M | 0.1% |
1,964
| – | – |
|
67
Spyre Therapeutics
SYRE
$9.39B
| $2.52M | 0.09% |
107,310
-55,085
| -34% | -$1.86M |
|
68
Intuitive Surgical
ISRG
$134B
| $2.31M | 0.09% |
5,200
| – | – |
|
|
TRML
69
DELISTED
Tourmaline Bio
TRML
| $1.61M | 0.06% |
125,000
| – | – |
|
|
70
Cigna
CI
$73.3B
| $1.59M | 0.06% |
4,800
-132,339
| -96% | -$45.6M |
|
71
Avantor
AVTR
$9.78B
| $1.52M | 0.06% |
71,850
| – | – |
|
72
IQVIA
IQV
$42.8B
| $1.52M | 0.06% |
7,175
| – | – |
|
73
Stryker
SYK
$126B
| $1.48M | 0.05% |
4,360
| – | – |
|
74
Medtronic
MDT
$119B
| $1.37M | 0.05% |
17,460
| – | – |
|
|
LKFT
75
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
| $1.17M | 0.04% |
47,200
| – | – |
|
Similar funds
Aaron Cowen's Q2 2024 Portfolio in Review
As of Q2 2024, Aaron Cowen held 110 positions worth $2.72B, up 1.1% from $2.69B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Aaron Cowen deployed $160M of net new capital in Q2 2024, opening 9 new positions and adding to 24 existing holdings. Its largest new stake was Sysco: 520,900 shares worth $37.2M.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 60% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Cigna, an estimated $45.6M trimmed.
- Aaron Cowen's largest Q2 2024 buy was Sysco: 520,900 shares worth $37.2M.
- Aaron Cowen added most to UnitedHealth in Q2 2024, an estimated $71.7M increase.
- Aaron Cowen's biggest Q2 2024 reduction was Cigna, cutting an estimated $45.6M.
- Aaron Cowen fully exited argenx in Q2 2024, selling an estimated $48M.
- Aaron Cowen's ten largest holdings make up 48% of its $2.72B portfolio in Q2 2024.
- Aaron Cowen opened 9 new positions and closed 12 in Q2 2024.
- Aaron Cowen's portfolio value rose 1.1% quarter-over-quarter to $2.72B.
Based on Suvretta Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.